CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

Inclusion Criteria:

• 1. Gender unlimited，18<Age;
• 2. Diagnosed as Autoimmune Diseases（Systemic Lupus Erythematosus，Immune nephritis,Systemic sclerosis，Dermatomyositis，Neuromyelitis optica）and after routine treatment (using more than 2 types drugs, such as hormones andImmunosuppressants，Immunomodulator or Biological agents) are ineffective for more than 6 months or reappear with disease activity and/or no effective treatment after diseaseremission
• 3. Estimated life expectancy of minimum of 12 weeks;
• 4. The blood routine meets the following standards:

1. Lymphocyte count>0.3×10e9/L;
2. Neutrophils ≥0.5×10e9/L;
3. Hemoglobin ≥60g/L;
4. Platelet ≥30×10e9/L

• 5. Pregnant/lactating women, or male or female patients who have fertility and arewilling to take effective contraceptive measures at least 6 months after the last cellinfusion during the study period;
• 6.Those who voluntarily participated in this trial and provided informed consent;

Exclusion Criteria:

• 1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascularischemia, and cerebrovascular hemorrhagic diseases;
• 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severearrhythmia in the past;
• 3.Pregnant or lactating women (the safety of this therapy for unborn children is stillunknown)
• 4. Patients with HIV infection
• 5. Active infection of hepatitis B virus or hepatitis C virus;
• 6. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulationsignal;
• 7. Creatinine>176.8 umol/L, or ALT / AST > 3 times of normal amounts, or bilirubin>51umol/L;
• 8. Any unsuitable to participate in this trial judged by the investigator;
• 9. Individuals who have received CAR-T therapy, CAR-NK therapy, or any other genemodified cell therapy product within 3 months;
• 10. Received immunosuppressive therapy within one week prior to mononuclear cellcollection；
• 11. ndividuals who have used systemic steroid drugs exceeding 20mg/d of prednisone orequivalent doses within one week prior to treatment (excluding those who have recentlyor are currently using inhaled steroids)；
• 12. Any situation that researchers believe may increase the risk to the subjects orinterfere with the trial results.